about
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epitheliumA three-dimensional multivariate image processing technique for the analysis of FTIR spectroscopic images of multiple tissue sections.Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancerThe risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis.Is colposcopy needed following laser ablation for dysplasia?Precancerous changes in the cervix and risk of subsequent preterm birth.Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.Hormonal treatment of endometrial cancer.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenClearance of human papillomavirus in women treated for cervical dysplasia.Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlationsCurrent academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.VIN 3: a clinicopathologic review.CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis.Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.Limitations of the clonal agar assay for the assessment of primary human ovarian tumour biopsies.Integration of new or experimental treatment options and new approaches to clinical trials.3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004.Chapter 8: Screening for cervical cancer in developing countries.Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.Hormone replacement therapy and risk of epithelial ovarian cancer.Clinical trials in gynecological cancer.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burdenEpithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.First-line therapy in ovarian cancer trials.Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.Intraperitoneal distribution imaging in ovarian cancer patients.Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition.Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells.Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.
P50
Q27851868-6818C9E7-E277-41EB-8326-BCCD9CE02277Q29030494-6D6FF5C3-1978-42D8-A1CE-6954D8184A9EQ30478052-6C0FF885-78E2-4EDE-B6C1-50C1D54A0480Q30763413-30991BDE-6787-41A7-BD26-09B26780F2E9Q31004566-C6A69250-5049-4A98-B5C6-0F28DFA3F16AQ33256418-298F4FB0-3862-4449-A688-50933C8A71B1Q33262645-AEEB4016-CAA0-4DAD-9885-FFB6088309E3Q33378843-108CEEB9-4BA8-471F-BE64-3C6186180A2AQ33541943-BE1E720F-0012-4CEB-A5A1-B44168C155F6Q33628532-2996CE57-9D18-4B02-AC40-8141EF0CAFCDQ33776669-1BAFB035-0CEA-46C2-9544-93E3BC849F8BQ33848273-E9A637BD-0247-486F-A308-AB7179004344Q34390396-185B433B-DB87-49CB-97E1-E5D90C9F8098Q34442318-9103A143-7F79-4E95-B152-56FFB92C1F84Q34941554-3CBD2765-EF2F-4B3A-A044-AC1499815CF3Q35015117-0A823C40-1FBE-468E-8C8E-FB1E76BFED48Q35063442-530EE05C-571B-4650-A9BC-D01B55B00C84Q35906208-1FDD7027-9518-4022-894C-3C3970C8296DQ35913775-407F0735-C871-45E0-BD5F-8D3BD88D8187Q36046590-01A28FE4-B953-4203-BC22-705EBC1786A6Q36292554-9F8F9D08-72AE-4E0A-BF3B-8FA1C79E521DQ36292560-C6E6FCF6-26AA-42A5-967C-41938D2724CEQ36292568-E7B1BE02-2188-4D73-A9CB-CE6F48BF7963Q36584429-7D475AFF-8454-4501-BA67-5C736E578033Q36615765-DBD7B226-AF17-4B4D-8948-7BC19533BF8EQ36616741-8D5E3946-230D-455F-B1A3-90E8B9CBA2A6Q36619751-2602A8DF-2506-4381-8169-E983C29C2C72Q36823042-1B3FCC5B-4128-4CB9-BFA8-2F5ECAC58F18Q36891437-BA9DEE08-8CEF-4573-B311-BC88EA9FA135Q36914343-F07B8E54-4557-4FF9-B825-11380E390A58Q37017023-F27CA1E7-6DCB-40E6-BE42-C829F72A09A5Q37705457-F9636480-9C55-45CB-8102-579CE51565E5Q37872166-EC579F86-42EA-4933-BDFE-8EE1E1ABB4F8Q38034167-0CC6D868-58CC-4A2C-8D92-5008A82A4733Q38356887-DA4A30BE-2962-4B5B-9A69-23D6EA85C8EFQ39535066-C1FCFC29-428E-4595-8B67-10CC6115759CQ39936525-AB73DC74-8DBA-4322-834E-C52A030396A5Q40172148-BCA237D2-8790-4A3E-9F7B-DF6B5B277D1AQ40279036-12738BE3-9D21-4E90-884A-DC5D4164914CQ40352144-812DFC2A-26C8-47A9-AD14-834E4302A68C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael A. Quinn
@ast
Michael A. Quinn
@en
Michael A. Quinn
@es
Michael A. Quinn
@nl
Michael A. Quinn
@sl
type
label
Michael A. Quinn
@ast
Michael A. Quinn
@en
Michael A. Quinn
@es
Michael A. Quinn
@nl
Michael A. Quinn
@sl
prefLabel
Michael A. Quinn
@ast
Michael A. Quinn
@en
Michael A. Quinn
@es
Michael A. Quinn
@nl
Michael A. Quinn
@sl
P106
P1153
7202672447
P21
P31
P496
0000-0003-0694-3870